Myoferlin, a multifunctional protein in normal cells, has novel and key roles in various cancers

Wei Zhu¹,² | Bolun Zhou¹,² | Chenxuan Zhao¹,² | Zhengqing Ba¹,² | Hongjuan Xu¹,² | Xuejun Yan¹,² | Weidong Liu¹,² | Bin Zhu¹,² | Lei Wang¹,² | Caiping Ren¹,²

¹The NHC Key Laboratory of Carcinogenesis and The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Xiangya Hospital, Central South University, Changsha, Hunan, China
²Cancer Research Institute, Collaborative Innovation Center for Cancer Medicine, School of Basic Medical Science, Central South University, Changsha, Hunan, China

Abstract
Myoferlin, a protein of the ferlin family, has seven C2 domains and exhibits activity in some cells, including myoblasts and endothelial cells. Recently, myoferlin was identified as a promising target and biomarker in non-small-cell lung cancer, breast cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, colon cancer, melanoma, oropharyngeal squamous cell carcinoma, head and neck squamous cell carcinoma, clear cell renal cell carcinoma and endometrioid carcinoma. This evidence indicated that myoferlin was involved in the proliferation, invasion and migration of tumour cells, the mechanism of which mainly included promoting angiogenesis, vasculogenic mimicry, energy metabolism reprogramming, epithelial-mesenchymal transition and modulating exosomes. The roles of myoferlin in both normal cells and cancer cells are of great significance to provide novel and efficient methods of tumour treatment. In this review, we summarize recent studies and findings of myoferlin and suggest that myoferlin is a novel potential candidate for clinical diagnosis and targeted cancer therapy.

KEYWORDS
angiogenesis, cancer, metastasis, myoferlin, therapeutic target, vesicle trafficking

1 | BACKGROUND

Myoferlin is a relatively novel membrane-anchored protein within the ferlin family. The myoferlin gene is located at chromosome 10q23.33. It was initially found to have a high degree of homology to dysferlin, and the percentage of similarity between myoferlin and dysferlin sequences is 69%.¹ Dysferlin gene mutations cause Miyoshi myopathy and limb girdle muscular dystrophy type 2B,²...
while mutations in myoferlin are not correlated with human disease in previous studies. However, myoferlin functions have been revealed through animal and cytology experiments. Elimination of myoferlin in mice results in smaller myofibres and a dystrophic phenotype that has a decreased capacity to regenerate after injury. In the hindlimb muscles of resistance exercise-trained rats, myoferlin mRNA was highly up-regulated.4 In quadriceps biopsies from Duchenne muscular dystrophy patients, myoferlin mRNA was also up-regulated 7.3-fold.5 Of note, recent studies suggest that myoferlin participates in the proliferation, invasion and metastasis of multiple cancers. In addition, researchers regard myoferlin as a promising target and biomarker. In this review, we will present a summary of the functions and roles of myoferlin in normal and tumour cells with updated knowledge.

2 | THE STRUCTURE OF MYOFERLIN

Myoferlin belongs to the ferlin family, which has a single pass transmembrane domain situated at the carboxy-terminus in common.6 The ferlin family is composed of five different proteins, namely, dysferlin, myoferlin, otoferlin, Fer1L5 and Fer1L6.7 All of the ferlin family proteins contain various C2 domains (C2B, C2C, C2D, C2E and C2F) and a carboxy-terminal transmembrane domain. Dysferlin, myoferlin and Fer1L5 contain the C2A and DYSF domains. Otoferlin also contains the C2A domain.7 In the ferlin family, myoferlin shares more similarities with dysferlin compared with other ferlin proteins.3 Myoferlin and dysferlin are both 230 kD proteins that contain seven C2 domains and one carboxy-terminal transmembrane domain that is a membrane-spanning protein domain. Myoferlin and dysferlin both contain a DYSF domain and are highly expressed in myoblasts. An interesting feature of the DYSF structure is that it contains a DYSF domain within another DYSF domain due to gene duplication, but the function of the DYSF domain still remains unknown.8 Mature myofibres express dysferlin and myoferlin at the plasma membrane.1,3 Furthermore, myoferlin contains some positively charged residues that are important for allowing the transmembrane domain to anchor within the membrane.7 Myoferlin is highly expressed in skeletal muscle, heart muscle and endothelial cells and is also expressed in lungs and most other tissues at low levels.5 Myoferlin typically works with the help of C2 domains. Each C2 domain is formed by approximately 100 amino acids. Two C2-domains (C2A and C2B) are found in the cytoplasmic domain of synaptotagmin I. Synaptotagmin I works as a Ca2+ sensor that facilitates membrane fusion. C2 domains typically function by two mechanisms: binding phospholipids and playing roles in protein-protein interactions.9 The C2 domain at the amino terminus of myoferlin, C2A, binds negatively charged phospholipids in response to calcium and is highly expressed in myoblasts undergoing fusion. The C2A domain of myoferlin only binds to phospholipid mixtures that have a high fraction of phosphatidylserine.10 This domain is ideally located to mediate vesicle trafficking directly.11 The second domain of myoferlin, C2B, binds to EH-domain-containing 2 (EHD2) directly. Thus, myoferlin is implicated in both endocytic-recycling and clathrin-mediated endocytosis.12 Of note, the C2D domain is a target of WJ460, a novel small molecule compound, which exhibits high therapeutic significance in various tumours.13 The structure of myoferlin is shown in Figure 1.

3 | FUNCTIONS OF MYOFERLIN IN NORMAL CELLS

3.1 | Muscle cells

Skeletal muscle has inherent renewal properties that allow for regeneration and on-going repair. The individual muscle cells are highly dependent on an effective and rapid vesicle trafficking system for efficient repair and growth.14 Vesicle trafficking system is crucial for many cellular functions, including cell division, cell migration and the regulation of signalling. In addition, the capacity to coordinate actin dynamics promoting cytoskeletal rearrangements plays an important role during myogenesis.15 Myoferlin functions in some of the above-mentioned activities, and a summary of these mechanisms is presented in Figure 2.

3.1.1 | Essential for vesicle trafficking and muscle growth

Members of the EH-domain-containing (EHD) family act in the process of endocytosis and endocytic recycling, which mediate lipid and receptor recycling back to the plasma membrane.36 Myoferlin functions in this process as a critical participant with an asparagine-proline-phenylalanine motif in the myoferlin C2B domain and binds directly to EHD2, an EHD family molecule that is responsible for vesicular trafficking.

**FIGURE 1** The structure of myoferlin. Myoferlin is a protein that is composed of 2061 amino acids and contains seven C2 domains (referred to C2A-G), a DYSF domain and a carboxy-terminal transmembrane domain. C2A binds to negatively charged phospholipids; C2B binds to EHD2.
Insulin-like growth factor (IGF) is an important protein in the regulation of muscle growth, and its function is mediated by binding to the IGF1 receptor (IGF1R) then activating MAPK and AKT pathways. In developing myofibres, IGF1 stimulation induces muscle fibre hypertrophy. Myoferlin targets EHD2 to impact the translocation and recycling of IGF1R and is a modulator of muscle growth. In detail, myoferlin internalizes IGF1R and is subsequently shuttled back to the cell surface to bind more IGF1 in further rounds. In myoferlin-null myoblasts, large vesicular structures are formed by the accumulation of IGF1R, and the receptors cannot be shuttled back to the membrane. In addition, EHD2 induces myotube formation, which is also affected by myoferlin.

3.1.2 | Mediating the fusion of myoblasts
Myoferlin is highly expressed for myoblast fusion. Myoferlin plays an important role in the formation of the myotubes by the fusion of singly nucleated myoblasts during the regeneration of mature muscle and embryonic muscle growth. Mechanically, it has been demonstrated that myoferlin is necessary for calcium-sensitive membrane resealing via the C2A domain, which can promote the fusion of two opposed lipid bilayers. Furthermore, myoferlin interacts with EHD2 to regulate myoblast fusion by regulating reorganization or disassembly of the cytoskeleton given that the C2B domain of myoferlin can directly bind to EHD2 and compete with EHD2-binding protein 1 (EHBP1), the binding partner of EHD2.

3.1.3 | Promoting skeletal muscle repair
Skeletal muscle contains multinucleated myofibres, and myoferlin promotes their growth and repair by inducing mononucleated myoblasts to fuse with other mononucleated myoblasts and myoblasts to fuse to myotubes. Nuclear factor of activated T cells (NFAT) is expressed in muscle and works at different periods during the process of muscle growth and differentiation. NFAT targets a 1543-bp fragment of the myoferlin promoter to induce the expression of myoferlin, which contributes significantly to the adaptation occurring in skeletal muscle during ground squirrel hibernation.

3.2 | Endothelial cells

3.2.1 | Positively regulating VEGFR-2
Myoferlin is highly expressed in vascular tissues and endothelial cells (ECs), which are especially enriched in CEM/LR (caveolae-enriched buoyant membrane microdomains/lipid raft) microdomains.

**FIGURE 2** Models for myoferlin and EHD2 in vesicle cycling and myoferlin expression in damaged myofibres. Myoferlin and EHD2 are implicated in vesicle cycling. After endocytosis, some receptors and their ligands are internalized and then are shuttled to the endocytic-recycling compartment. Finally, they are shuttled back to the membrane and work in another round. EHD2 binds directly to myoferlin in the endocytic-recycling compartment and promotes the cyclic process of insulin-like growth factor receptor (IGFR). IGF binds to IGFR directly to promote cell growth by activating the Akt/mTOR and MAPK pathway. In injured myofibres, Ca²⁺ flows into the cytoplasm and activates NFATs. NFAT then binds to the promoter of the myoferlin and increases the expression of myoferlin. Ca²⁺ influx is sensed by myoferlin and initiates dynamin-dependent endocytosis, which cooperates with caveolin. The budded caveolae are then shuttled to the damaged area by an exocytic repair model.
Myoferlin functions in migration, proliferation and nitric oxide (NO) release, which occur in response to vascular endothelial growth factor (VEGF). In addition, myoferlin is necessary in some plasma membrane events, such as signalling in specialized cells. The loss of myoferlin reduces the autophosphorylation and expression of VEGF receptor-2 (VEGFR-2) in native ECs. The transfection of myoferlin increases autophosphorylation in response to VEGF and VEGFR-2 membrane expression in a reconstituted cell system. A complex is formed by myoferlin, which also contains dynamin-2 and VEGFR-2. This protein complex is necessary for the surface expression of VEGFR-2. This complex prevents proteasomal degradation and CBL-dependent VEGFR-2 polyubiquitination, which increases functional signalling and VEGFR-2 protein stability. Myoferlin depletion disrupts rapid VEGF-mediated intracellular signalling pathways and attenuates VEGF-mediated activation of key intracellular signalling cascades, that is, c-Jun N-terminal kinase (JNK), phospholipase Cγ (PLCγ) and extracellular signal-regulated kinase-1/2 (ERK-1/2).

3.2.2 | Up-regulating Tie-2

Myoferlin is required for proper tyrosine kinase receptors expression at the plasma membrane. Myoferlin knockdown in ECs decreases the expression of a second tyrosine kinase receptor, Tie-2, which is a well-described angiogenic receptor. A study demonstrated that myoferlin gene silencing results in oedema formation and attenuates angiogenesis. Post-translational regulation of many tyrosine kinase receptors requires myoferlin, including VEGFR-2 and Tie-2. Acute myoferlin knockdown may exhibit anti-angiogenic effects and act as an anti-angiogenesis target in the treatment of cancer or other angiogenesis-related diseases.

3.2.3 | Modulating receptor-dependent endocytosis

Myoferlin induces endomembrane fusion with the plasma membrane in endothelial cells. Myoferlin also regulates aspects of receptor-dependent endocytosis. Myoferlin gene silencing decreases caveolea/raft-dependent endocytosis, whereas ectopic myoferlin expression increases endocytosis in COS-7 cells. Mechanistically, myoferlin partially colocalizes with caveolin-1 (Cav-1) and dynamin-2 (Dyn-2) to form a protein complex, which participates in membrane fusion and caveolae-dependent endocytosis. Current research defines this complex as a molecular bandage that may be essential to the integrity of the cellular membrane. The molecular bandage may also provide a method to regulate various disease processes.

4 | ROLES OF MYOFERLIN IN CANCERS

Recently, myoferlin has roles in various cancers, and current studies suggest that myoferlin is a promising target and biomarker. Myoferlin is involved in the proliferation, invasion and migration of cancer cells via different mechanisms, mainly including promoting angiogenesis, vasculogenenic mimicry, energy metabolism reprogramming, epithelial-mesenchymal transition (EMT) and affecting exosomes. Clinically, myoferlin levels correlate with histologic grade and prognosis in several types of cancers. Of note, the functions and mechanisms of myoferlin in cancers have not been thoroughly revealed to date. As myoferlin is considered a highly potential therapeutic target, further exploration is required. Myoferlin expression in cancers has been recently assessed and is presented in Table 1 below.

### Table 1: Expression of myoferlin in cancers

| Cancer               | Total no. of samples | Positive rate | Correlation of myoferlin level and tumour stage or grade | References |
|----------------------|----------------------|---------------|----------------------------------------------------------|------------|
| NSCLC                | 148                  | 50.7%         | Stage: No correlation observed (P = .632)                | 42         |
| Breast cancer        | 90                   | No accurate data | Stage: Positive correlation                              | 13         |
| PAC                  | 154                  | 41.6%         | Histologic grade: Positive correlation                   | 43         |
| HCC                  | 138                  | No accurate data | Stage or grade: No correlation observed                  | 44         |
| Melanoma             | 52                   | 42.3%         | Pathological grade: No correlation observed (P = .190)   | 37         |
| Colon cancer         | 28                   | 76%           | Prognostic or TNM stage: No correlation observed         | 38         |
| OPSCC                | 211                  | 78.2%         | T stage: Positive correlation*                           | 45         |
| HNSCC                | 20                   | No accurate data | Not mentioned                                            | 46         |
| ccRCC                | 304b                 | No accurate data | Fuhrman nuclear grade: Positive correlation              | 47         |
| Endometrioid carcinoma | 60                 | 96.7%         | FIGO stage: Negative correlationf                       | 48         |

*aCorrelation between nuclear myoferlin expression and tumour stage.

b304 samples were gathered from 152 patients.

cCorrelation between myoferlin and FIGO stage or FIGO histologic grading showed a negative correlation (opposite to the results in other cancers), the mechanism of which had not been fully revealed (see Section 4.2.7).
4.1 | Overview

4.1.1 | Promoting proliferation, invasion and migration

Unregulated proliferation is one of the major characteristics of tumour cells. Researchers observed that myoferlin protein is essential for the proliferation of breast cancer and pancreatic ductal adenocarcinoma (PDAC) cells.\(^\text{34,36}\)

Epithelial-mesenchymal transition is a common phenomenon and a crucial step in the progression and dissemination of cancer metastasis.\(^\text{49}\) Functionally, myoferlin can induce EMT via up-regulating mesenchymal cell markers, such as fibronectin and vimentin, and co-ordinately down-regulating epithelial markers, such as E-cadherin.\(^\text{35,40}\)

A mathematical model prediction reveals that matrix metalloproteinases (MMPs) have a key function on cancer cell invasion.\(^\text{50}\) Myoferlin can also cause selective changes of MMPs in breast cancer\(^\text{40,50}\) and melanoma.\(^\text{37}\)

A summary of these mechanisms is shown in Figure 3.

4.1.2 | Functions in exosomes

Exosomes, which are characterized by unique proteomic composition, participate in the intercellular exchange of metabolites, proteins and nucleic acids.\(^\text{51}\) Through proteomic analysis, myoferlin has been reported in several tumour-derived exosomes, including prostate cancers,\(^\text{52}\) bladder cancers,\(^\text{53}\) colon cancers,\(^\text{54}\) ovary cancers,\(^\text{55}\) Hepatocellular carcinoma,\(^\text{56}\) squamous carcinoma cells\(^\text{57}\) and melanoma.\(^\text{58}\)

Blomme et al\(^\text{41}\) revealed that myoferlin is an emerging oncogene that plays a functional role in exosome biology. Myoferlin is potentially involved in protein loading of exosome. The authors note that myoferlin is a general component of exosomes derived from pancreatic and breast cancer cell lines, and myoferlin-depleted exosomes exhibit a reduced capacity to transfer nucleic acids to human endothelial cells, thus reducing the ability to induce proliferation and migration of human endothelial cells.

4.1.3 | Promoting angiogenesis/

![Figure 3](attachment:figure3.png)

**Figure 3** Myoferlin plays key roles in the development of cancer cells. A, Myoferlin is essential for the secretion of VEGF and the function of VEGFR, which promotes angiogenesis and vasculogenic mimicry in cancer cells. Myoferlin has a significant function in IL-6-mediated tumour growth and tumour metastasis through promoting the nuclear translocation of STAT3. Furthermore, WJ460 binds to the C2D domain of myoferlin, which is considered a potential therapeutic target. B, Myoferlin depletion modulates MAPK and p16-\(\text{P}^0\)/Rb pathways and induces senescence. Myoferlin depletion decreases the capacity of exosomes and TGF-\(\beta\) secretion, which has a negative function in EMT and migration. Myoferlin depletion also has an effect on endosomal and metabolism systems and inhibits cancer cell proliferation.
vasculogenic mimicry

Myoferlin gene knockdown attenuates the expression of VEGFR-2 and Tie-2, well-described angiogenic receptors, in endothelial cells. However, in several cancer cells, myoferlin also has another role. A recent study reported that myoferlin overexpression induced the formation of vasculogenic mimicry in melanoma. Concrete mechanisms are discussed in the next section. The mechanism and the exact regulatory system are presented in Figure 4.

4.1.4 | Promoting energy metabolism reprogramming

Energy metabolism reprogramming is considered an emerging hallmark and a therapeutic target in cancers for cancer cells mostly prefer to perform with glycolysis to produce energy. But cancer cells with more flexible metabolic phenotype have stronger resistance. In triple-negative breast cancer, and colon cancer cells, myoferlin was described as an essential molecule to maintain a high oxidative phosphorylation activity. The mechanism will be discussed in the next section.

4.1.5 | Clinical significance

Myoferlin plays an oncogenic role and promotes cancer cell metastasis; thus, it often exhibits a relationship with histological grade or clinical stage of cancers. In addition, overexpression of myoferlin often indicates a poor prognosis. Specifically, myoferlin is an independent prognostic factor in pancreatic adenocarcinoma, andopharyngeal squamous cell carcinoma, and head and neck squamous cell carcinoma patients. Clear cell renal cell carcinoma, colon cancer, and non-small-cell lung carcinoma patients.

4.2 | Specific roles of myoferlin in different cancers

4.2.1 | Myoferlin in non-small-cell lung carcinoma

Lung cancer is a major cause of cancer-related deaths worldwide. Non-small-cell lung cancer (NSCLC) accounts for approximately 85%-90% of all lung cancers. Myoferlin is expressed in normal lung parenchyma and normal bronchial epithelium. A recent study found that myoferlin localizes to the cytoplasm of the cells in all NSCLC pathological subtypes, and adenocarcinomas exhibited the largest proportion. Moreover, in adenocarcinoma cases, myoferlin-positive tumours may indicate a poor prognosis (odds ratio = 2.94; P = .339), while myoferlin and VEGFR-2 expression exhibited a significant correlation in squamous cell carcinoma (P = .001), especially in stage I patients.

4.2.2 | Myoferlin in breast cancer

Female breast cancer is the second commonly diagnosed cancer in the world and the leading cause of cancer-associated death in females. Studies have shown that myoferlin plays a critical role in cancer progression via various mechanisms. For migration, researchers found that myoferlin depletion enhances cell adhesion, enlarges focal adhesion, enhances cell-matrix adhesion through elevating focal adhesion kinase and paxillin phosphorylation, redirects cancer cell motility and subsequently inhibits migration.

In molecular level, potential targets of myoferlin include MMPs, EGFR and TGF-β. After knocking-down myoferlin, mesenchymal to

![Diagram showing the role of myoferlin in cancer cells and endothelial cells.](https://via.placeholder.com/150)
epithelial transition occurred, and selective changes in MMPs were observed (which included remarkable down-regulation of MMP1, MMP3, and MMP9). Up-regulation of MMP9, EGF-induced cell migration and EMT were blocked by impaired degradation of phosphorylated EGFR via dysfunctional plasma membrane caveolae and alteration of caveolin homo-oligomerization and bio-mechanical properties were altered (cell stiffness decreased, cell-substrate adhesion increased, and cells subsequently migrated directionally, collectively and slowly). In addition, vesicle traffic was impaired (saturated/unsaturated fatty acids were subsequently re-programmed to glycosylation, the ability to balance between oxidative phosphorylation and glycolysis was reduced, and the sensitivity to metabolic drug increased), growth velocity was reduced (partly for myoferlin-dependent plasma membrane fusion and fission events were inhibited). Moreover, the overall migration ability of the tumour decreased (due to the abovementioned mechanisms, and reduced autocrine TGF-β production caused dysregulation of TGF-β1 signalling). Of note, the author stated that mechanism by which myoferlin regulates TGF-β1 secretion may occur altered gene expression or exocytosis, which deserves further study. Of note, Zhang et al. found that myoferlin was directly targeted by WJ460 and suggest that targeting myoferlin by WJ460 may be a promising therapeutic strategy in myoferlin-driven breast cancers.

### 4.2.3 | Myoferlin in pancreatic adenocarcinoma

Pancreatic cancer is one of the deadliest cancers given its poor prognosis. Similarly, high myoferlin levels are a risk factor in pancreatic adenocarcinoma (PAC). Myoferlin expression significantly correlates with the degree of histological differentiation of PAC, and reduced myoferlin expression alleviated malignant phenotypes of both primary and metastatic PAC cells. Exosomes have various roles in PDAC, mainly including local invasion, migration, immune evasion and therapeutic resistance. Myoferlin is critical for producing functional exosomes with sufficient quantities of certain components.

Autocrine and paracrine of vascular endothelial growth factor A (VEGFA) have pro-proliferative effects independently. Myoferlin knockdown down-regulated VEGFA secretion, which is caused by impairment of VEGFA exocytosis, subsequently, tumours lacked VEGFA and VEGFA induced functional blood vessels thus exhibited a reduced volume. In addition, myoferlin is required to maintain a branched mitochondrial structure and high oxidative phosphorylation activity. Myoferlin depletion induces the phosphorylation of dynamin-related protein (DRP)-1 and increases its abundance, thus leading to mitochondrial fission and swelling. Interestingly, depletion of myoferlin led to a reduction in autophagy induction. Li et al. reported lead compound 6y, one of 1,5-diaryl-1,2,4-triazole derivatives, bound to myoferlin and inhibited pancreatic cancer metastasis. The anticancer activity of 6y is positively associated with the expression of myoferlin, and 6y is insensitive to myoferlin depletion. The specific mechanisms may be mediated by blocking the receptor tyrosine kinases, inhibiting the secretions of matrix metalloproteinase and reversing the EMT process. Overall, myoferlin may provide a novel therapeutic target in PAC.

### 4.2.4 | Myoferlin in hepatocellular carcinoma

In total, 75%-85% of liver cancer cases are hepatocellular carcinoma (HCC). HCC is often associated with poor prognosis. Hermans et al. demonstrated that myoferlin was necessary for invasion, proliferation and anchorage-independent cell growth of HCC, and the myoferlin gene is targeted by MKL1/2. Furthermore, myoferlin inhibits EGFR and the downstream MAPK and p16-Rb pathways, thus affecting senescence phenotype. In detail, depletion of myoferlin in tumour cells from SRF-VIP16-derived murine HCCs induced a senescence phenotype, which suggested that myoferlin might be a novel therapeutic target.

### 4.2.5 | Myoferlin in colon cancer

Colorectal cancer ranks third in terms of incidence but second in terms of mortality worldwide, and the most common tumour location is the proximal colon (41%) in America. Myoferlin's functions are similar to those in PAC. Myoferlin is required for high oxidative phosphorylation activity and maintenance of an organized mitochondrial network. In addition, Rademaker et al. also found that myoferlin silencing causes reactive oxygen species (ROS) accumulation, p53-dependent reduction of cell growth, enhanced DNA damage response and increased apoptosis. These authors revealed that myoferlin could represent a suitable target for new anticancer therapies.

### 4.2.6 | Myoferlin in melanoma

Melanoma is the most aggressive type of skin cancer, and the appearance of vasculogenic mimicry (VM) in this type of cancer always indicates a poor prognosis. In VM, tumour cells mimic true vascular endothelium cells and form microvascular channels. Myoferlin knockdown significantly impaired the capability of A375 cells to form VM structures and subsequently inhibit cell invasion and migration in vitro. At the molecular level, down-regulation of myoferlin decreases MMP-2 expression and induces MET. Thus, myoferlin may represent a biomarker for VM formation and a risk factor for poor prognosis of melanoma patients.

### 4.2.7 | Myoferlin in other cancers

Kumar et al. demonstrated that myoferlin could exist in the nucleus, cytosol or membrane of oropharyngeal squamous cell carcinoma (OPSCC) cells. These authors uncovered that nuclear myoferlin expression was directly associated with IL-6 (P < .001), inversely associated with HPV status (P = .0014) and could predict poor clinical outcome in OPSCC patients independently. Yadav et al. found that myoferlin is bound to EHD2 protein and 13.
modulates the IL-6/STAT3 signalling pathway, which regulates the expression of IL-6/STAT3 downstream genes, including snail and nanog, in head and neck squamous cell carcinoma (HNSCC) cell lines. Myoferlin knockdown significantly decreases tumour growth and metastasis of HNSCC. Song et al. uncovered that high myoferlin levels correlate with unfavourable prognosis in clear cell renal cell carcinoma (ccRCC) patients. Amazingly, in endometrioid carcinoma, high expression of myoferlin was related to low-grade carcinoma, while the loss of myoferlin expression was noted in high-grade carcinoma, which was in contrast to findings in other cancers. The authors pointed out it was probably due to the fact that normal endometrial tissue underwent a continuous cycle of regeneration, in which myoferlin was implicated. As non-cyclic continuous exposure to sex hormones contributes to the oncogenesis of endometrioid carcinoma, the authors predicted a potential correlation among cellular regeneration, hormonal effect and myoferlin expression. This finding may suggest that myoferlin plays a different role in endometrioid carcinoma, and the mechanism remains uncharacterized.

5 | CONCLUSION AND PROSPECT

Myoferlin is a membrane-anchored ferlin family protein. Myoferlin is highly expressed in skeletal muscle, heart muscle and endothelial cells and is essential for the growth, repair and normal function of cells as it modulates vesicle trafficking, cell fusion, receptor-dependent endocytosis and the expression of certain receptors. Myoferlin is also expressed in most other tissues at low levels. However, in specific tumours, myoferlin is overexpressed and plays critical roles. Myoferlin functions in the proliferation, invasion and migration of cancer cells through various mechanisms. These findings identify myoferlin as a novel potential candidate for clinical diagnosis and targeted therapy.

The latest research shows that myoferlin regulates cancer-derived exosomes and functions as a new player in exosome biology. As mentioned above, myoferlin impacts tumour-associated angiogenesis by affecting VEGFA secretion and EGFR activity. These findings suggest that myoferlin induces the malignant phenotype of cancers by altering the tumour microenvironment. Zhang et al. found that WJ460 directly targets myoferlin, interacts with myoferlin C2 domain and hampers the proper function of myoferlin. WJ460 represents a potentially effective therapeutic molecule for preventing myoferlin-related cancers and provides an opportunity for developing myoferlin-targeted agents. Moreover, lead compound 6y, one of the 1,5-diaryl-1,2,4-triazole derivatives, targets at myoferlin and prevents pancreatic cancer metastasis, which suggests 6y may also be a promising therapeutic strategy.

ACKNOWLEDGEMENTS

The present study was supported by the National Natural Science Foundation of China (grant nos. 81773179 and 81272972 [C. Ren]), the National Basic Research Program of China (2010CB833605 [C. Ren]), Program for New Century Excellent Talents in University (NCET-10-0790 [C. Ren]), the Hunan Provincial Science and Technology Department (grant no. 2016JC2049 [C. Ren]), Provincial Natural Science Foundation of Hunan (grant no. 2016JJ2172 [W. Liu]) and the Undergraduate Training Programs for Innovation and Entrepreneurship (UTPIE, 502331018 [W. Zhu]).

CONFLICT OF INTERESTS

The authors declare that they have no competing interests.

AUTHORS’ CONTRIBUTIONS

CR, WZ, BZ and CZ contributed to the study design. WZ, BZ and CZ drafted and critically revised the manuscript. CR, ZB, HX, XY, WL, BZ and LW discussed and revised the manuscript. All authors read and approved the final manuscript.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

ORCID

Chenxuan Zhao https://orcid.org/0000-0002-3966-4897

REFERENCES

1. Davis DB, Delmonte AJ, Ly CT, McNally EM. Myoferlin, a candidate gene and potential modifier of muscular dystrophy. Hum Mol Genet. 2000;9:217-226.
2. Liu J, Aoki M, Illa I, et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet. 1998;20:31-36.
3. Doherty KR, Cave A, Davis DB, et al. Normal myoblast fusion requires myoferlin. Development. 2005;132:5565-5575.
4. Adams GR, Haddad F, Bodell PW, Tran PD, Baldwin KM. Combined isometric, concentric, and eccentric resistance exercise prevents unloading-induced muscle atrophy in rats. J Appl Physiol (1985). 2007;103:1644-1654.
5. Haslett JN, Sanoudou D, Kho AT, et al. Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. Proc Natl Acad Sci USA. 2002;99:15000-15005.
6. Jimenez JL, Bashir R. In silico functional and structural characterisation of ferlin proteins by mapping disease-causing mutations and evolutionary information onto three-dimensional models of their C2 domains. J Neurol Sci. 2007;260:114-123.
7. Posey AD Jr, Demonbreun A, McNally EM. Ferlin proteins in myoblast fusion and muscle growth. Curr Top Dev Biol. 2011;96:203-230.
8. Sula A, Cole AR, Yeats C, Orengo C, Keep NH. Crystal structures of the human Dysferlin inner DysF domain. BMC Struct Biol. 2014;14:3.
9. Hui E, Bai J, Chapman ER. Ca2+-triggered simultaneous membrane penetration of the tandem C2-domains of synaptotagmin I. Biophys J. 2006;91:1767-1777.
10. Harsini FM, Bui AA, Rice AM, et al. Structural basis for the distinct membrane binding activity of the homologous C2A domains of myoferlin and dysferlin. J Mol Biol. 2019;431:2112-2126.
11. Davis DB, Doherty KR, Delmonte AJ, McNally EM. Calcium-sensi-
tive phospholipid binding properties of normal and mutant ferlin C2 
domains. J Biol Chem. 2002;277:22883-22888.
12. Grant BD, Caplan S. Mechanisms of EHD/RME-1 protein function in 
endocytic transport. Traffic. 2008;9:2043-2052.
13. Zhang T, Li J, He Y, et al. A small molecule targeting myoferlin ex-
erts promising anti-tumor effects on breast cancer. Nat Commun. 
2018;9:3726.
14. Grounds MD, Shavlakadze T. Growing muscle has different sar-
collemmal properties from adult muscle: a proposal with sci-
entific and clinical implications: reasons to reassess skeletal 
muscle molecular dynamics, cellular responses and suitability of 
experimental models of muscle disorders. BioEssays. 2011;33:
458-468.
15. Posey AD, Swanson KE, Alvarez MG, et al. EHD1 mediates vesicle 
trafficking required for normal muscle growth and transverse tu-
bule development. Dev Biol. 2014;387:179-190.
16. Naslavsky N, Caplan S. Mechanisms of EHD/RME-1 protein function in 
p-translocation. Trends Cell Biol. 2011;21:122-131.
17. Yang SY, Goldspink G. Different roles of the IGF-I Ec peptide (MGF) 
and mature IGF-I in myoblast proliferation and differentiation. FEBS 
Lett. 2002;525:156-160.
18. Musarò A, McCullagh K, Paul A, et al. Localized Igf-1 transgene 
expression sustains hypertrophy and regeneration in senescent ske-
letal muscle. Nat Genet. 2001;27:195-200.
19. Rommel C, Bodine SC, Clarke BA, et al. Mediation of IGF-1-induced 
skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/ 
Akt/GSK3 pathways. Nat Cell Biol. 2001;3:1009-1013.
20. Doherty KR, Demonbreun AR, Wallace GQ, et al. The endocytic re-
cycling protein EHD2 interacts with myoferlin to regulate myoblast 
fusion. J Biol Chem. 2008;283:20252-20260.
21. Demonbreun AR, Posey AD, Heretis K, et al. Myoferlin is required 
for insulin-like growth factor response and muscle growth. FASEB J. 
2010;24:1284-1295.
22. Guilherme A, Soriano NA, Bose S, et al. EHD2 and the novel EH 
domain binding protein EHB1 couple endocytosis to the actin cy-
toskeleton. J Biol Chem. 2004;279:10593-10605.
23. Demonbreun AR, Lapidos KA, Heretis K, et al. Myoferlin regulation 
by NFAT in muscle injury, regeneration and repair. J Cell Sci. 
2010;123:2413-2422.
24. Abbott KL, Friday BB, Thaloor D, Murphy TJ, Pavlath GK. 
Activation and cellular localization of the cyclosporine A-sensitive 
transcription factor NF-AT in skeletal muscle cells. Mol Biol Cell. 
1998;9:2905-2916.
25. Cho YY, Yao KE, Bode AM, et al. RSK2 mediates muscle cell 
differentiation through regulation of NFAT3. J Biol Chem. 
2007;282:8380-8392.
26. O’Connor RS, Mills ST, Jones KA, Ho SN, Pavlath GK. A combina-
torial role for NFAT5 in both myoblast migration and differ-
entiation during skeletal muscle myogenesis. J Cell Sci. 
2007;120:149-159.
27. Zhang Y, Storey KB. Expression of nuclear factor of activated T cells 
(NFAT) and downstream muscle-specific proteins in ground s quir-
rel skeletal and heart muscle during hibernation. Mol Cell Bioch. 
2016;412:27-40.
28. Bernatchez PN, Acevedo L, Fernandez-Hernando C, et al. Myoferlin 
regulates vascular endothelial growth factor receptor-2 stability 
and function. J Biol Chem. 2007;282:30745-30753.
29. Bernatchez PN, Sharma A, Kodaman P, Sessa WC, Myoferlin is crit-
ical for endocytosis in endothelial cells. Am J Physiol Cell Physiol. 
2009;297:C484-C492.
30. Bernatchez PN, Allen BG, Gélinas DS, Guillemette G, Sirois MG. 
Regulation of VEGF-induced endothelial cell PAF synthesis: role of 
p42/44 MAPK, p38 MAPK and PI3K pathways. Br J Pharmacol. 
2001;134:1253-1262.
31. Pan X, Liang L, Si RU, et al. Discovery of novel anti-angiogenesis 
agents. Part 10: multi-target inhibitors of VEGFR-2, Tie-2 and EphB4 
incorporated with 1,2,3-triazol. Eur J Med Chem. 2019;163:1-9.
32. Yu C, Sharma A, Tran A, Utokaparch S, Leung C, Bernatchez P. 
Myoferlin gene silencing decreases Tie-2 expression in vitro and 
angiogenesis in vivo. Vascul Pharmacol. 2011;55:26-33.
33. Cipta S, Patel HH. Molecular bandages: inside-out, outside-in repair 
of cellular membranes. Focus on "Myoferlin is critical for endocytosis 
in endothelial cells". Am J Physiol Cell Physiol. 2009;297:C481-C483.
34. Leung C, Yu C, Lin M, Tognoon C, Bernatchez P. Expression of 
myoferlin in human and murine carcinoma tumors: role in mem-
brane repair, cell proliferation, and tumorigenesis. Am J Pathol. 
2013;182:1900-1909.
35. Volakis LI, Li R, Ackerman WE, et al. Loss of myoferlin redirects 
breast cancer cell motility towards collective migration. PLoS ONE. 
2014;9:e86110.
36. Fahmy K, Gonzalez A, Arafa M, et al. Myoferlin plays a key role in 
VEGFA secretion and impacts tumor-associated angiogenesis in 
human pancreas cancer. Int J Cancer. 2016;138:652-663.
37. Zhang W, Zhou P, Meng A, et al. Down-regulating myoferlin inhib-
its the vasculoegenic mimicry of melanoma via decreasing MMP-2 
and inducing mesenchymal-to-epithelial transition. J Cell Mol Med. 
2018;22:1743-1754.
38. Rademaker G, Costanza B, Bellier J, et al. Human colon cancer cells 
highly express myoferlin to maintain a fit mitochondrial network 
and escape p53-driven apoptosis. Oncogene. 2019;8:21.
39. Rademaker G, Henneguëre V, Brohé L, et al. Myoferlin con-
trols mitochondrial structure and activity in pancreatic ductal 
adenoacarcinoma, and affects tumor aggressiveness. Oncogene. 
2018;37:4398-4412.
40. Li R, Ackerman WE, Mihai C, Volakis LI, Ghadiiali S, Kniss DA. 
Myoferlin depletion in breast cancer cells promotes mesenchy-
mal to epithelial shape change and stalls invasion. PLoS ONE. 
2012;7:e39766.
41. Blomme A, Fahmy K, Peulen O, et al. Myoferlin is a novel exosom-
al protein and functional regulator of cancer-derived exosomes. 
Oncotarget. 2016;7:83669-83683.
42. Song DH, Ko GH, Lee JH, et al. Myoferlin expression in non-small 
cell lung cancer: prognostic role and correlation with VEGFR-2 ex-
pression. Oncol Lett. 2016;11:998-1006.
43. Wang W-S, Liu X-H, Liu L-X, et al. iTRAQ-based quantitative pro-
teomics reveals myoferlin as a novel prognostic predictor in pancre-
atic adenocarcinoma. J Proteomics. 2013;91:453-465.
44. Hermanns C, Hampl V, Holzer K, et al. The novel MKL target gene 
myoferlin modulates expansion and senescence of hepatocellular 
carcinoma. Oncogene. 2017;36:3464-3476.
45. Kumar B, Brown NV, Swanson BJ, et al. High expression of myofer-
lin is associated with poor outcome in oropharyngeal squamous cell 
carcinoma patients and is inversely associated with HPV-status. 
Oncotarget. 2016;7:18665-18677.
46. Yadav A, Kumar B, Lang JC, Teknos TN, Kumar P. A muscle-specific 
protein ‘myoferlin’ modulates IL-6/STAT3 signaling by chaperoning 
activated STAT3 to nucleus. Oncogene. 2017;36:6374-6382.
47. Song DH, Ko GH, Lee JH, et al. Prognostic role of myoferlin ex-
pression in patients with clear cell renal cell carcinoma. Oncotarget. 
2017;8:89033-89039.
48. Kim MH, Song DH, Ko GH, et al. Myoferlin expression and its cor-
relation with FIGO histologic grading in early-stage endometrioid 
carcinoma. J Pathol Transl Med. 2018;52:93-97.
49. Mao X-Y, Li Q-Q, Gao Y-F, Zhou H-H, Liu Z-J, Qin W-L. Gap junction 
membrane repair, cell proliferation, and tumorigenesis. Trends Cell Biol. 
2016;36:133-137.
50. Eisenberg MC, Kim Y, Li R, Ackerman WE, Kniss DA, Friedman A. 
Mechanistic modeling of the effects of myoferlin on tumor cell in-
vansion. Proc Natl Acad Sci U S A. 2011;108:20078-20083.
51. Hu Y, Rao S-S, Wang Z-X, et al. Exosomes from human umbilical cord blood accelerate cutaneous wound healing through miR-21-3p-mediated promotion of angiogenesis and fibroblast function. Theranostics. 2018;8:169-184.

52. Kharaziha P, Chioureas D, Rutishauser D, et al. Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. Oncotarget. 2015;6:21740-21754.

53. Welton JL, Khanna S, Giles PJ, et al. Proteomics analysis of bladder cancer exosomes. Mol Cell Proteomics. 2010;9:1324-1338.

54. Demory Beckler M, Higginbotham JN, Franklin JL, et al. Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. Mol Cell Proteomics. 2013;12:343-355.

55. Liang B, Peng P, Chen S, et al. Characterization and proteomic analysis of ovarian cancer-derived exosomes. J Proteomics. 2013;80:171-182.

56. He M, Qin H, Poon T, et al. Hepatocellular carcinoma-derived exosomes promote motility of immortalized hepatocyte through transfer of oncogenic proteins and RNAs. Carcinogenesis. 2015;36:1008-1019.

57. Park JE, Tan HS, Datta A, et al. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics. 2010;9:1085-1099.

58. Lazar I, Clement E, Ducoux-Petit M, et al. Proteome characterization of melanoma exosomes reveals a specific signature for metastatic cell lines. Pigment Cell Melanoma Res. 2015;28:464-475.

59. Yuan LW, Yamashita H, Seto Y. Glucose metabolism in gastric cancer: the cutting-edge. World J Gastroenterol. 2016;22:2046-2059.

60. Blomme A, Costanza B, de Tollio P, et al. Myoferlin regulates cellular lipid metabolism and promotes metastases in triple-negative breast cancer. Oncogene. 2017;36:2116-2130.

61. Yadav A, Kumar B, Datta J, Teknos TN, Kumar P. IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res. 2011;9:1658-1667.

62. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.

63. Leung C, Shaheen F, Bernatchez P, Hackett TL. Expression of myoferlin in human airway epithelium and its role in cell adhesion and zonula occludens-1 expression. PLoS ONE. 2012;7:e40478.